Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

ABSTRACT:

Background

Among the aggressive non-small-cell lung carcinoma subtypes, pulmonary sarcomatoid carcinoma (PSC) is a rare and poorly understood tumor. This study was undertaken to evaluate the efficacy [progression-free survival (PFS) and overall survival (OS)] of first-line immune checkpoint inhibitor (ICI) with or/without (±) chemotherapy (ChT) versus ChT alone against advanced PSCs (APSCs).

Patients and methods

Using the French Epidemiological Strategy and Medical Economics Lung Cancer (ESME-LC) database (2015-2022), we analyzed APSC patients' first-line ICI ± ChT or ChT outcomes, then applied propensity score weighting to indirectly compare them.

Results

Among 42 219 patients with untreated lung cancers, 229 (0.5%) had APSCs. One hundred and sixty-one (70.3%) receiv

SUBMITTER: Amrane K 

PROVIDER: S-EPMC12309934 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature